AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Here's Why

Key Points

• AbCellera shares opened sharply lower, falling from a previous close of $9.76 to $9.22 before recovering to around $9.69. The decline followed a recent rally driven by positive clinical news.
• ABCL635 produced positive Phase 2 results for reducing moderate-to-severe hot flashes, prompting Truist to raise its price target from $12 to $30 and increasing bullish options activity.
• Risks remain significant: AbCellera proposed a $200 million share and warrant offering that could dilute shareholders, while the company continues to report negative earnings and revenue below expectations; analysts’ consensus rating is “Moderate Buy” with a $12.83 target.

AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $9.76, but opened at $9.22. AbCellera Biologics shares last traded at $9.6910, with a volume of 2,981,112 shares.

Key Headlines Impacting AbCellera Biologics

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: ABCL635 delivered positive Phase 2 results. The non-hormonal treatment met its primary efficacy endpoints, significantly reducing the frequency and severity of moderate-to-severe hot flashes. The results represent an important clinical validation for AbCellera’s first internally developed pipeline candidate and helped drive a sharp increase in the stock. AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results
• Positive Sentiment: Analyst optimism increased. Truist raised its price target for AbCellera from $12 to $30 and maintained a “buy” rating, reflecting the potential commercial value of ABCL635 and a more favorable view of the company’s pipeline. Truist Raises AbCellera Price Target
• Positive Sentiment: Trading activity signals increased bullish speculation. Investors purchased approximately 16,666 ABCL call options, about 151% above typical daily volume. This can amplify near-term momentum, though options activity is speculative rather than a measure of fundamental value. Investors Buy Large Volume of AbCellera Biologics Call Options
• Neutral Sentiment: Investors are divided on the longer-term outlook. Some analysts view the Phase 2 results as a major pipeline breakthrough, while others argue that the broader platform story is weakening and that additional development and regulatory milestones are needed before ABCL635 can support a sustained commercial revaluation. AbCellera Excellent Phase 2 Data in Menopause
• Negative Sentiment: AbCellera announced a proposed $200 million public offering. Issuing common shares and pre-funded warrants will provide cash for development but may dilute existing shareholders and could pressure the stock after its recent rally. AbCellera Announces Proposed Public Offering
• Negative Sentiment: Valuation risk has become more prominent. One analysis estimated ABCL could be about 33% overvalued following the Phase 2 announcement, highlighting the stock’s substantial run-up relative to AbCellera’s still-negative earnings, limited quarterly revenue and need for further clinical progress. AbCellera Could Be 33% Overvalued

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Truist Financial raised their price objective on AbCellera Biologics from $12.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday. Wall Street Zen cut shares of AbCellera Biologics from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Stifel Nicolaus lifted their price target on shares of AbCellera Biologics from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Weiss Ratings restated a "sell (d-)" rating on shares of AbCellera Biologics in a report on Friday, July 17th. Finally, Benchmark raised shares of AbCellera Biologics from a "hold" rating to a "buy" rating and set a $11.00 price objective for the company in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $12.83.

AbCellera Biologics Stock Up 2.9%

The company has a fifty day moving average price of $6.35 and a 200 day moving average price of $4.77. The stock has a market cap of $3.08 billion, a PE ratio of -18.59 and a beta of 1.20.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The company had revenue of $4.05 million for the quarter, compared to the consensus estimate of $7.85 million. AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%. As a group, research analysts predict that AbCellera Biologics Inc. will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in AbCellera Biologics during the 4th quarter valued at $26,938,000. Two Sigma Investments LP grew its holdings in AbCellera Biologics by 25.9% in the 3rd quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company's stock worth $26,031,000 after acquiring an additional 1,064,290 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of AbCellera Biologics by 1,636.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,344,485 shares of the company's stock valued at $14,858,000 after acquiring an additional 4,094,268 shares during the period. BlackRock Inc. purchased a new position in shares of AbCellera Biologics in the second quarter valued at about $29,872,000. Finally, Bank of America Corp DE raised its stake in shares of AbCellera Biologics by 13.9% during the first quarter. Bank of America Corp DE now owns 2,999,936 shares of the company's stock valued at $10,470,000 after acquiring an additional 367,064 shares during the last quarter. Institutional investors own 61.42% of the company's stock.

About AbCellera Biologics

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source